1,040 results on '"Massie, Barry M."'
Search Results
152. Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure
153. The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND‐HF Trial
154. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE
155. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals The ARB Trialists Collaboration
156. Variation in Use of Left Ventriculography in the Veterans Affairs Health Care System
157. Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?
158. Abstract 88: Preoperative Hyponatremia is Associated with Increased Risk of Heart Failure Hospitalization and Mortalityamong Veterans Undergoing Cardioverter-Defibrillator Implantation
159. Abstract 273: Incidence and Predictors of Heart Failure Hospitalization in Veterans Undergoing Cardioverter-Defibrillator Implantation in the Outcomes among Veterans with Implantable Defibrillators (OVID) Registry
160. Abstract 86: Rates and Association of Risk Factors with Device Infection in Veterans Undergoing Cardioverter-Defibrillator Implantation Enrolled in the OVID Registry
161. Clinical Pharmacy Services in Heart Failure: An Opinion Paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network
162. Abstract 83: Association of Preoperative Anemia with Heart Failure Hospitalization and Mortality among Veterans Undergoing Cardioverter-Defibrillator
163. The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure
164. Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure
165. Long-term electrical survival analysis of Riata and Riata ST silicone leads: National Veterans Affairs experience
166. Abstract 9181: Does a Low Ejection Fraction Predict Mortality? Insights From the ASCEND-HF Trial
167. CTST-21: A Phase 2, Randomized, Double-Blind, Multi-Center Study Comparing 15G Cross-Linked Polyelectrolyte (CLP) versus Placebo in Heart Failure Patients with Chronic Kidney Disease
168. Anticoagulation in heart failure: current status and future direction
169. Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction
170. Response to Letters Regarding Article, “Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction”
171. The PROTECT in‐hospital risk model: 7‐day outcome in patients hospitalized with acute heart failure and renal dysfunction
172. Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction
173. Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure
174. Novel targets for the treatment of heart failure: Perspectives from a heart failure clinician and trialist
175. Relation of Peripheral Collagen Markers to Death and Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction
176. Prognostic Value of Baseline Plasma Amino-Terminal Pro-Brain Natriuretic Peptide and Its Interactions With Irbesartan Treatment Effects in Patients With Heart Failure and Preserved Ejection Fraction
177. Characteristics of Implantable Cardioverter-defibrillator Recipients for the Primary and Secondary Prevention of Sudden Cardiac Death in the Outcomes Among Veterans With Implantable Defibrillators (OVID) Registry
178. Globalization of Clinical Trials
179. Reply
180. Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction
181. ACCF/AHA/HFSA 2011 Survey Results: Current Staffing Profile of Heart Failure Programs, Including Programs That Perform Heart Transplant and Mechanical Circulatory Support Device Implantation
182. Body Mass Index and Adverse Cardiovascular Outcomes in Heart Failure Patients With Preserved Ejection Fraction
183. Guidelines are Merely Guidelines
184. Factors Associated With Outcome in Heart Failure With Preserved Ejection Fraction
185. Coronary Morbidity and Mortality, Pre-existing Silent Coronary Artery Disease, and Mild Hypertension
186. Heart Failure Guidelines, Performance Measures, and the Practice of Medicine
187. Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart Failure
188. History of Heart Failure and Mortality among Veterans With Implantable Cardioverter-Defibrillators
189. Clinical Subtype of Atrial Fibrillation at the Time of Implantation and Subsequent Mortality among Veterans With Implantable Defibrillators
190. Is the effect of angiotensin receptor blockade in patients with heart failure modified by treatment with aspirin? The answer is not so clear!
191. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60‐day outcomes in the PROTECT pilot study
192. Mode of Death in Patients With Heart Failure and a Preserved Ejection Fraction
193. Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes
194. BASELINE SYSTOLIC BLOOD PRESSURE AND OUTCOMES IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION - RESULTS FROM THE I-PRESERVE TRIAL
195. ACUTE CORONARY SYNDROMES IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION: A HARBINGER OF DEATH?
196. Baseline Plasma NT-proBNP and Clinical Characteristics: Results From the Irbesartan in Heart Failure With Preserved Ejection Fraction Trial
197. The Journal of Cardiac Failure: Passing the Baton
198. Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function
199. Resource Use and Costs of Treatment With Anticoagulation and Antiplatelet Agents: Results of the WATCH Trial Economic Evaluation
200. Response to Letter Regarding Article, “Randomized Trial of Warfarin, Aspirin, and Clopidogrel in Patients With Chronic Heart Failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) Trial”
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.